Search results
Showing 376 to 390 of 1561 results for do not do recommendations
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.
This quality standard covers the safe and effective use of medicines. It covers people of all ages who are taking medicines, including those who are not getting the full benefit from their medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS120Show all sections
Sections for QS120
- Quality statements
- Quality statement 1: Shared decision-making
- Quality statement 2: Patient involvement in reporting medicines-related patient safety incidents
- Quality statement 3: Learning from medicines-related patient safety incidents
- Quality statement 4: Medicines reconciliation in acute settings
- Quality statement 5: Medicines reconciliation in primary care
- Quality statement 6: Structured medication review
- About this quality standard
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)
This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.
This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.
Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)
Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults.
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.
View quality statements for QS178Show all sections
Sections for QS178
- Quality statements
- Quality statement 1: Asking people about their sexual history
- Quality statement 2: Discussing prevention and testing with people who are at risk of sexually transmitted infections
- Quality statement 3: Condom distribution schemes
- Quality statement 4: Access to sexual health services
- Quality statement 5: Repeat testing for sexually transmitted infections
- Quality statement 6: Partner notification
- Update information
This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings. It includes preventing healthcare-associated infections that develop because of treatment or from being in a healthcare setting. It describes high-quality care in priority areas for improvement.
View quality statements for QS61Show all sections
Sections for QS61
- Quality statements
- Quality statement 1: Antimicrobial stewardship
- Quality statement 2: Organisational responsibility
- Quality statement 3: Hand decontamination
- Quality statement 4: Urinary catheters
- Quality statement 5: Vascular access devices
- Quality statement 6: Educating people about infection prevention and control
- Update information
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
This quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.
Sickle cell disease: managing acute painful episodes in hospital (CG143)
This guideline covers managing acute painful sickle cell episodes in children, young people and adults who present at hospital, from presentation until when they are discharged. It aims to reduce variation in how acute episodes are managed in hospital, focusing on effective, prompt and safe pain relief.